AIMSEvidence suggests that the rate of oral drug absorption changes during early childhood. Yet, respective clinical implications are currently unclear, particularly for preterm neonates. The objective of this study was to evaluate changes in oral drug absorption after birth for different Biopharmaceutics Classification System (BCS) class I and II compounds to better understand respective implications for paediatric pharmacotherapy.
METHODSTwo paradigm compounds were selected for BCS class I (paracetamol (acetaminophen) and theophylline) and II (indomethacin and ibuprofen), respectively, based on the availability of clinical literature data following intravenous and oral dosing. A comparative population pharmacokinetic analysis was performed in a step-wise manner in NONMEM® 7.2 to characterize and predict changes in oral drug absorption after birth for paracetamol, theophylline and indomethacin.
RESULTSA one compartment model with an age-dependent maturation function for oral drug absorption was found appropriate to characterize the pharmacokinetics of paracetamol. Our findings indicate that the rate at which a drug is absorbed from the GI tract reaches adult levels within about 1 week after birth. The maturation function for paracetamol was found applicable to theophylline and indomethacin once solubility limitations were overcome via drug formulation. The influence of excipients on solubility and, hence, oral bioavailability was confirmed for ibuprofen, a second BCS class II compound.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Preterm birth is associated with high morbidity and mortality resulting in a high demand for drug therapy.• Clinical evidence suggests that the oral absorption process of a drug undergoes substantial changes after birth. The impact of these physiological changes on oral drug therapy is currently unclear.
WHAT THIS STUDY ADDS• This study improves our understanding of changes in oral drug absorption in preterm neonates for two drugs from both BCS class I and BCS class II.• Our findings indicate that these changes in oral absorption within the first few days after birth are a system-specific property, which can be used to guide oral dosing of BCS class I and BCS class II compounds in preterm neonates.